| Heading: |
Methylphenidate and Pancreatic Enzyme Replacement Therapy: Import Duties |
| Question ID: |
1795173 |
| UIN: |
46602 |
| House: |
Commons |
| Date tabled: |
2025-04-17 |
| Asking Member ID: |
5335 |
| Asking Member display name: |
Jess Brown-Fuller
|
| Asking Member handle: |
JessBrownFuller
|
| Asking Member Twitter reference: |
@JessBrownFuller
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of US tariffs on the domestic supply of (a) methylphenidate and (b) pancreatic enzyme replacement therapy. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-04-29 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Department is working closely with life sciences stakeholders and other Government departments to assess the potential impact of United States tariffs on global medicine supply chains. We have a range of well-established processes to mitigate risks to... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |